Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GSK3536867 in Healthy Adults
NCT05613205Phase 1Completed
- Sponsor
- GSK
- Start
- Nov 2022
- Primary completion
- Dec 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of GSK3536867 in typhoid fever and paratyphoid fever, sponsored by GSK. Primary endpoints: Number of Participants With Solicited Administration-site Events After the First Vaccination, Number of Participants With Solicited Administration-site Events After the Second Vaccination and 7 more. Started Nov 2022; status: completed.
02
Drugs
GSK3536867
03
Conditions
typhoid feverparatyphoid fever
Beyond the preview
Go deeper on NCT05613205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05613205.